Leukemia section

Leukemia News and Features

Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera

Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera

[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia

Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.

High Symptom Burden With Polycythemia Vera Linked to QoL Impairment

High Symptom Burden With Polycythemia Vera Linked to QoL Impairment

Patients with polycythemia vera enrolled in the REVEAL trial have high symptom burden resulting in substantial physical and emotional quality of life impairment and notable work productivity loss.

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs